» Articles » PMID: 30908791

Standards of Medical Care for Type 2 Diabetes in China 2019

Abstract

The prevalence of diabetes in China has increased rapidly from 0.67% in 1980 to 10.4% in 2013, with the aging of the population and westernization of lifestyle. Since its foundation in 1991, the Chinese Diabetes Society (CDS) has been dedicated to improving academic exchange and the academic level of diabetes research in China. From 2003 to 2014, four versions of Chinese diabetes care guidelines have been published. The guidelines have played an important role in standardizing clinical practice and improving the status quo of diabetes prevention and control in China. Since September 2016, the CDS has invited experts in cardiovascular diseases, psychiatric diseases, nutrition, and traditional Chinese medicine to work with endocrinologists from the CDS to review the new clinical research evidence related to diabetes over the previous 4 years. Over a year of careful revision, this has resulted in the present, new version of guidelines for prevention and care of type 2 diabetes in China. The main contents include epidemiology of type 2 diabetes in China; diagnosis and classification of diabetes; primary, secondary, and tertiary diabetes prevention; diabetes education and management support; blood glucose monitoring; integrated control targets for type 2 diabetes and treatments for hyperglycaemia; medical nutrition therapy; exercise therapy for type 2 diabetes; smoking cessation; pharmacologic therapy for hyperglycaemia; metabolic surgery for type 2 diabetes; prevention and treatment of cardiovascular and cerebrovascular diseases in patients with type 2 diabetes; hypoglycaemia; chronic diabetic complications; special types of diabetes; metabolic syndrome; and diabetes and traditional Chinese medicine.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.


Prevalence, Awareness, Treatment, and Control of Diabetes Among 0.98 Million Patients With Stroke/TIA in China: Insights From a Nationwide Cohort Study.

Chen S, Yalkun G, Gu H, Yang X, Wang C, Zhao X J Diabetes. 2025; 17(3):e70059.

PMID: 40025409 PMC: 11872597. DOI: 10.1111/1753-0407.70059.


Impact of community public health care on treatment effect, health cognition, and self-management in patients with type 2 diabetes.

Shi H, Liu C, Luo H World J Clin Cases. 2025; 13(5):95183.

PMID: 39959766 PMC: 11606368. DOI: 10.12998/wjcc.v13.i5.95183.


Classification and identification of risk factors for type 2 diabetes.

Tang S, Zhao X, An X, Sun W, Kang X, Sun Y World J Diabetes. 2025; 16(2):100371.

PMID: 39959280 PMC: 11718467. DOI: 10.4239/wjd.v16.i2.100371.


Determining the status of small dense low-density lipoprotein cholesterol level in women undergoing menopausal transition.

He Q, Fang Y, Wang L, Liang M, Chen X, Hu R Front Endocrinol (Lausanne). 2025; 15:1500712.

PMID: 39902165 PMC: 11788168. DOI: 10.3389/fendo.2024.1500712.